<DOC>
	<DOCNO>NCT01506713</DOCNO>
	<brief_summary>The objective study compare rate extent absorption Dr. Reddy 's Laboratories Ltd , clopidogrel Bristol-Myers Squibb Company , USA Plavix® , clopidogrel 75 mg tablet fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Clopidogrel Tablets 75 mg Dr. Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>Randomized , Open-label , 2-Way Crossover , Bioequivalence Study Clopidogrel 75 mg Tablet ( Dr. Reddy 's Laboratories Ltd. , India ) Plavix® ( Bristol-Myers Squibb Company , USA ) Following 75 mg Dose In Healthy Subjects Under Fasting Conditions .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may use various medium type ( e.g . radio , newspaper , Anapharm Web site , Anapharm volunteer ' database ) . Subjects must meet follow criterion include study : Male female , nonsmoker , ≥18 ≤55 year age . Medically healthy clinically normal laboratory profile , vital sign ECG . Capable consent . BMI ≥19.0 &lt; 30.0 Subjects follow applies exclude study : Clinically significant illness surgery within 4 week prior dose . Any clinically significant abnormality abnormal laboratory test result find medical screening . Any reason , opinion Clinical Sub.investigator , would prevent subject participate study . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , or• heart rate le 50 J00 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ J Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) , positive alcohol breath test screening . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine ( PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction clopidogrel relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fIuoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior dose . Clinically significant history presence gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthe counter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Use tobacco product 3 month precede drug administration . Any food allergy , intolerance , restriction special diet , opinion Clinical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration . Positive urine pregnancy test screening . Breastfeeding subject . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . Acceptable method contraception : intrauterine contraceptive device ( place least 4 week prior study drug administration ; condom diaphragm + spermicide ; hormonal contraceptive ( start least 4 week prior study drug administration ) . History known active pathological bleeding ( e.g . peptic ulcer , intracranial hemorrhage ) . Increased risk bleed ( e.g . frequent nose bleeding , recent trauma , surgery pathological condition ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>